Cell therapy manufacturing is uniquely vulnerable to contamination, variability, and operational burden because the product - living cells - is not amenable to terminal sterilization or sterile filtration. Consequently, manipulation conducted as an open operation elevates sterility risk and drives facility, people, and process complexity. Regulatory guidance (EU GMP Annex 1:2022; FDA aseptic processing guidance) emphasizes a holistic contamination control strategy (CCS) and risk‑based adoption of closed, sterile, and increasingly automated systems to improve sterility assurance, scalability, inspection readiness, and cost efficiency.  

This article clarifies what “open” vs “closed” means in practice, why closing open steps is essential for GMP compliance and patient safety, how closure accelerates both autologous scale‑out and allogeneic scale‑up, and what it does for cost, speed, and tech transfer. 

1) Open vs. Closed Manufacturing Systems 

Open systems (what they are and why they persist) 

An open step exposes product or product‑contact surfaces to the room environment (e.g., uncapped vessels, pipetting into open flasks, aseptic additions in a Biosafety Cabinet (BSC)). These manipulations are typically executed in Grade A unidirectional airflow within Grade B background rooms, with sterility assurance relying on operator technique, environmental quality, and facility controls. 

Inherent challenges of open operations: 

• Elevated exposure to airborne bioburden and particulates from operators, air handling, and materials.  

• Operator‑dependent variability (gowning, aseptic behaviors), which regulators scrutinize via environmental monitoring and aseptic process simulation (APS/media fills).  

• High facility burden: Grade A/B areas, frequent interventions, and intensive environmental monitoring.  

• Scalability limitations: each open manipulation consumes BSC time, cleanroom capacity, and skilled staff.  

Closed systems (what “closed” really means) 

A closed system maintains a sealed sterile boundary, so materials move through sterile connectors, tubing welds, single‑use assemblies, or fully enclosed/automated hardware without product exposure to room environment.  

Defining features: 

• Validated sterile boundaries and transfers (aseptic tube welds; pre‑sterilized connectors; preassembled manifolds).  

• Single‑use flow‑paths that eliminate cleaning and reduce cross‑batch risk. 

• Automation/semi‑automation to reduce manual touchpoints and operator variability.  

2) Why Closing Open Steps Is Important for GMP Compliance 

Since cell therapies are not terminally sterilized, aseptic controls must be robust from end to end. Regulators expect minimization of environmental exposure and clear justification for any remaining open manipulations, supported by APS/media fills and a documented CCS.  

Regulatory drivers: 

• Minimize exposure risk: Each open operation adds contamination probability. Annex 1 elevates CCS, QRM, and APS expectations; FDA’s aseptic guidance similarly emphasizes rigorous controls for open steps.  

• Room classification flexibility via closure: Validated closed steps can often run in lower grades with appropriately justified CCS, reducing interventions and monitoring burden.  

• Multi‑product and multi‑batch suitability: Closed systems reduce cross‑contamination risk in ballroom layouts running parallel batches - critical for autologous operations. FDA notes ballroom designs for closed systems are acceptable if controls are process‑appropriate.  

• Alignment with risk‑based expectations: Cell therapy developers that proactively close processes are better positioned for inspections.  

3) Reducing Contamination Risk and Protecting Patients 

Contaminated runs are irretrievable and typically must be discarded. This outcome is especially critical for autologous products, where each batch corresponds to a single patient, and can be operationally disastrous in the case of large allogeneic lots. 

Why closure helps: 

• Physical isolation of product from operators and room air.  

• Fewer manual interventions; fewer opportunities for human error.  

• Single‑use consumables eliminate cleaning/sterilization carryover and reduce bioburden risk.  

• Consistent sterile boundary across unit operations.  

4) Scalability: Autologous Scale‑Out and Allogeneic Scale‑Up 

Autologous therapies (scale‑out) 

Autologous manufacturing requires many parallel patient‑specific batches. Running open steps across numerous BSCs is rarely scalable. Closed and ideally automated platforms enable parallelization in ballroom settings, reduce reliance on highly specialized aseptic operators, and improve batch‑to‑batch reproducibility.  

Closure unlocks: 

• Parallel processing without multiplying Grade B suites.  

• Lower operator dependency and training burden.  

• Modular layouts with multiple closed units in a controlled (often lower‑grade) environment.  

Allogeneic therapies (scale‑up) 

Allogeneic platforms need to handle high volumes and integrate multiple unit operations, such as seed train, expansion, harvest, wash/concentration, and fill/finish. Open handling of large volumes is not practical; instead, closed bioreactors and downstream processes are necessary. 

Closure enables: 

• Fully closed feed/transfer lines across bioreactors and downstream processing.  

• Closed washing/concentration and aseptic filling with pre‑assembled single‑use paths.  

• Greater batch consistency at scale with clear CCS documentation.  

5) Cost and Operational Efficiency 

Many believe closed systems are more expensive, but despite higher upfront costs for equipment or disposables, overall expenses usually decrease due to facility downgrades, lower environmental monitoring, and fewer deviations. 

Where savings accrue: 

• Cleanroom footprint and utilities: Closed steps permit operating in lower classifications (where justified), decreasing air change rates, gowning, and cleaning; this reduces energy and carbon footprint.  

• Labor efficiency: Fewer manual manipulations; one operator can supervise multiple runs with automation and integrated single‑use kits.  

• Higher batch success: Fewer contamination events mean fewer product failures, deviations, and investigations.  

• Faster buildout and flexibility: Less Grade B infrastructure and a modular, single‑use strategy accelerate facility fit‑out and future expansion.  

6) Time to Market and Product Availability 

Cycle time compression: Open manipulations multiply set‑ups, sanitization, BSC turnover, and gowning. Closed connectors and automated platforms reduce hands‑on time between steps.  

Avoid late‑stage remediation: Leaving open steps in early phases invites late regulatory expectations to close them, this may require more extensive comparability packages, APS redesign, and potential approval delays. A phase‑appropriate plan that moves toward closure and consistent aseptic boundaries de‑risks late development. 

Smoother tech transfer: Closed, modular, single‑use flows reduce site‑to‑site variation, since equipment and consumable sets are standardized. 

Higher commercial throughput: Manual open processing is inherently capacity‑constrained. Closure supports parallelization (autologous) or increased batch size (allogeneic). 

7) A Practical Guide: “How‑To” Close Processes 

Map the process. Define precisely where sterility must be maintained from first aseptic step to final container closure and simulate it appropriately (APS).  

Unit‑operation checklist (typical CGT workflow): 

• Cell receipt & thaw: Implement automated dry bath thawing devices to increase process consistency and minimize risk of contamination.  

• Selection/activation/transduction/expansion: Employ closed single‑use flow paths (tubing welds or sterile connectors) to transfer material (reagents, virus, media etc.) into culture vessels.  

• Sampling & analytics: Use closed sampling ports and aseptic sampling devices to avoid opening loops; align with at‑line/inline analytics under CCS.  

• Harvest/wash/concentration: Use closed centrifugation/filtration with sterile connections to harvest and formulate.  

• Formulation/fill/finish: Prefer closed, pre‑sterilized filling manifolds and connectors. 

Validate “closure.” Document integrity of the closed path (supplier integrity documentation, leak testing strategy, weld/connector validation, bioburden controls) as part of your CCS and qualification packages.  

Design the facility around closure. Use risk assessments to set area classification, personnel flows, and segregation appropriate for closed vs open operations.  

Plan APS/media fills that reflect reality. Ensure simulations encompass all open manipulations that remain to design robust APS runs.  

Adopt phase‑appropriate CMC strategy. FDA’s CGT guidance supports risk‑based, lifecycle CMC with clear expectations for documenting changes and maintaining comparability as you close and automate through development.  

Conclusion 

Reducing open steps in cell therapy manufacturing is fundamental not only to engineering optimization, but also to ensuring patient safety, regulatory compliance, scalability, cost management, and reduced time-to-market. For autologous therapies, closure reduces reliance on high‑grade cleanrooms and manual aseptic work enabling parallelization without compromising sterility. For allogeneic therapies, achieving closure enables large-scale, interconnected processes to be both feasible and compliant with regulatory standards. Designing for closure early avoids costly late‑phase remediation and positions programs for smoother inspections and commercial expansion.